Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.78 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28200818 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL379156 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL18240167 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL4155101 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL379158 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL23027722 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL18240169 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL16599896 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL2476433 | 1.00 | FAAH (0.78) | FAAHEPHX2MEN1KMT2ACNR1 | |
| SCHEMBL6287721 | 0.95 | MEN1 (0.77) | FAAHMEN1KMT2ACNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | FAAH 2901/4885EPHX2 3168/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.